Mitochondrial DNA Copy Number Is a Potential Biomarker for Treatment Choice Between Metformin and Acarbose
Clinical Pharmacology & Therapeutics · 2023
DOI: 10.1002/cpt.2877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Jing Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Metformin is the first‐line drug for type 2 diabetes (T2D) while acarbose is suggested as a viable alternative in Chinese patients with newly diagnosed T2D. However, few biomarkers have been established to guide the choice between these two agents. Mitochondrial DNA (mtDNA) copy number (mtDNA‐CN) is a biomarker of mitochondrial function, which is associated with various metabolic outcomes. Using data from the trial of Metformin and Acarbose in Chinese as the Initial Hypoglycaemic Treatment (MARCH) (metformin n = 214; acarbose n = 198), we examined whether mtDNA‐CN was associated with response to the drugs in terms of glycemic response and β‐cell function protection response. The glycemic response is defined as the maximum glucose reduction of glycated hemoglobin A 1c , fasting plasma glucose, or postprandial blood glucose during 48 weeks. β‐cell function protection response is defined as the maximum increment of insulinogenic index (IGI) or disposition index (DI). For all three glycemic responses, mtDNA‐CN was not significantly associated with either metformin or acarbose. Importantly, for β‐cell function protection response, we found the increased mtDNA‐CN was significantly associated with more IGI increment (beta: 0.84; 95% confidence interval (CI), 0.02 to 1.66) in the metformin group, but less IGI increment (beta: −1.38; 95% CI, −2.52 to −0.23) in the acarbose group. A significant interaction ( P = 0.008) between mtDNA‐CN and the treatment group was observed. Consistent results were also obtained when DI increment was used as a measure of β‐cell function response. This study demonstrated the potential application of mtDNA‐CN in guiding the treatment choice between metformin and acarbose based on β‐cell protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
- Department of Endocrinology and Metabolism, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
- Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- Department of Endocrinology of the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, Hefei, China.
- Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, China.
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Jing Wang, Kaixin Zhou
Zitieren
APA
Wang, J., Liang, H., Wang, Y., Zheng, X., Chen, F., Shao, J., Geng, Z., Zheng, L., Yang, W., Weng, J., Xu, T., & Zhou, K. (2023). Mitochondrial DNA Copy Number Is a Potential Biomarker for Treatment Choice Between Metformin and Acarbose. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2877
Vancouver
Wang J, Liang H, Wang Y, Zheng X, Chen F, Shao J, et al. Mitochondrial DNA Copy Number Is a Potential Biomarker for Treatment Choice Between Metformin and Acarbose. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2877
BibTeX
@article{Wang2023,
author = {Wang, Jing and Liang, Hua and Wang, You and Zheng, Xueying and Chen, Fei and Shao, Jian and Geng, Zhaoxu and Zheng, Li and Yang, Wenying and Weng, Jianping and Xu, Tao and Zhou, Kaixin},
title = {Mitochondrial DNA Copy Number Is a Potential Biomarker for Treatment Choice Between Metformin and Acarbose},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
doi = {10.1002/cpt.2877}
}
EUVIMED